The following excerpt was taken from PR Newswire– continue reading here.
NEW YORK, Dec. 10, 2025 /PRNewswire/ — Formation Bio and Lynk Pharmaceuticals today announced Formation Bio’s acquisition of worldwide rights, excluding Greater China, to LNK01006, a next generation central nervous system (CNS)–penetrant highly selective TYK2 inhibitor. The asset will be developed within Formation’s newly formed subsidiary Bleecker Bio.
LNK01006 recently received IND clearance from the FDA to initiate first-in-human studies in the US. Formation Bio plans to initiate a Phase 1 study in the first half of 2026, reflecting the company’s growing momentum in building a diverse portfolio of high-potential, clinical-stage assets.
LNK01006 is a next-generation, CNS-penetrant allosteric TYK2 inhibitor that combines potent, selective inhibition of TYK2-mediated cytokine signaling with a pharmacologic profile optimized for central immune modulation. Its potential best-in-class selectivity and CNS exposure are designed to regulate immune signaling within the central nervous system, potentially modulating the immune responses implicated in a range of autoimmune and inflammatory diseases. Its unique pharmacologic profile offers optionality to explore indications where central or compartmentalized immune pathways are believed to play a key role.
Under the terms of the agreement, Lynk will receive a minority equity stake in Bleecker Bio, an upfront payment and additional development, regulatory, and commercial milestones totaling up to $605 million US dollars and tiered royalties on potential future sales. Pacific Bridge NY, a New York-based investment fund specializing in supporting companies through late preclinical and clinical development, is a minority co-investor in Bleecker Bio.